Carly Miller

Employment

• University of Minnesota

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (21)

• Validation and testing of an in vitro model to study medical treatments for anterior urethral stricture disease: assessing the potential efficacy of phosphodiesterase-4 (PDE4) inhibition and testosterone
  2026 DOI: 10.64898/2026.05.13.724950
  +Save
• The Influence of the Germline HSD3B1 Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate Cancer
  Samuel Kellen, Allison Makovec, Carly D. Miller +12 more
  Cancers 2025 DOI: 10.3390/cancers17081270
  +Save
• Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
  Expert Review of Anticancer Therapy 2024 DOI: 10.1080/14737140.2024.2405103
  +Save
• Data from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.c.7260484.v1
  +Save
• Data from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.c.7260484
  +Save
• FIGURE 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934128.v1
  +Save
• FIGURE 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934128
  +Save
• FIGURE 2 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934125.v1
  +Save
• FIGURE 2 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934125
  +Save
• FIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934122
  +Save
• FIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  2024 DOI: 10.1158/2767-9764.25934122.v1
  +Save
• FIGURE 4 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  2024 DOI: 10.1158/2767-9764.25934119.v1
  +Save
• FIGURE 4 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934119
  +Save
• FIGURE 5 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  2024 DOI: 10.1158/2767-9764.25934116.v1
  +Save
• FIGURE 5 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934116
  +Save
• FIGURE 6 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  2024 DOI: 10.1158/2767-9764.25934113.v1
  +Save
• FIGURE 6 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934113
  +Save
• Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  Cancer Research Communications 2024 DOI: 10.1158/2767-9764.CRC-23-0546
  +Save
• Supplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  2024 DOI: 10.1158/2767-9764.25934110.v1
  +Save
• Supplemental Figure 1 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
  Carly D. Miller, John R. Lozada, Nicholas A. Zorko +20 more
  2024 DOI: 10.1158/2767-9764.25934110
  +Save